These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 29065822)
41. Foreword. Trypanosomatid disease drug discovery and target identification. N Setzer W Future Med Chem; 2013 Oct; 5(15):1703-4. PubMed ID: 24144406 [No Abstract] [Full Text] [Related]
42. Biological evaluation of glycosyl-isoindigo derivatives against the pathogenic agents of tropical diseases (malaria, Chagas disease, leishmaniasis and human African trypanosomiasis). Bouchikhi F; Anizon F; Brun R; Moreau P Bioorg Med Chem Lett; 2011 Nov; 21(21):6319-21. PubMed ID: 21937228 [TBL] [Abstract][Full Text] [Related]
43. Drug Design and Development for Neglected Diseases. Ferreira EI Curr Med Chem; 2019; 26(23):4298-4300. PubMed ID: 31618168 [No Abstract] [Full Text] [Related]
44. Phospholipid Analogues as Chemotherapeutic Agents Against Trypanosomatids. Chazapi E; Magoulas GE; Prousis KC; Calogeropoulou T Curr Pharm Des; 2021; 27(15):1790-1806. PubMed ID: 33302850 [TBL] [Abstract][Full Text] [Related]
45. Marine alkaloids as bioactive agents against protozoal neglected tropical diseases and malaria. Tempone AG; Pieper P; Borborema SET; Thevenard F; Lago JHG; Croft SL; Anderson EA Nat Prod Rep; 2021 Dec; 38(12):2214-2235. PubMed ID: 34913053 [TBL] [Abstract][Full Text] [Related]
46. A review of QSAR studies to discover new drug-like compounds actives against leishmaniasis and trypanosomiasis. Castillo-Garit JA; Abad C; Rodríguez-Borges JE; Marrero-Ponce Y; Torrens F Curr Top Med Chem; 2012; 12(8):852-65. PubMed ID: 22352913 [TBL] [Abstract][Full Text] [Related]
47. Dual Inhibition of Parasitic Targets: A Valuable Strategy to Treat Malaria and Neglected Tropical Diseases. Previti S; Di Chio C; Ettari R; Zappalà M Curr Med Chem; 2022; 29(17):2952-2978. PubMed ID: 34375176 [TBL] [Abstract][Full Text] [Related]
48. [New drugs for the treatment of human parasitic protozoa]. Dupouy-Camet J Parassitologia; 2004 Jun; 46(1-2):81-4. PubMed ID: 15305692 [TBL] [Abstract][Full Text] [Related]
49. 4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis. Saad SM; Ghouri N; Perveen S; Khan KM; Choudhary MI Eur J Med Chem; 2016 Jan; 108():13-20. PubMed ID: 26619389 [TBL] [Abstract][Full Text] [Related]
50. New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape. Machado-Silva A; Guimarães PP; Tavares CA; Sinisterra RD Expert Opin Ther Pat; 2015 Mar; 25(3):247-60. PubMed ID: 25530084 [TBL] [Abstract][Full Text] [Related]
51. Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents. Kryshchyshyn A; Kaminskyy D; Karpenko O; Gzella A; Grellier P; Lesyk R Eur J Med Chem; 2019 Jul; 174():292-308. PubMed ID: 31051403 [TBL] [Abstract][Full Text] [Related]
52. Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? Ennes-Vidal V; Menna-Barreto RF; Branquinha MH; Dos Santos AL; D'Avila-Levy CM Parasitology; 2017 Feb; 144(2):117-123. PubMed ID: 27869056 [TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes. Bhambra AS; Edgar M; Elsegood MRJ; Li Y; Weaver GW; Arroo RRJ; Yardley V; Burrell-Saward H; Krystof V Eur J Med Chem; 2016 Jan; 108():347-353. PubMed ID: 26698538 [TBL] [Abstract][Full Text] [Related]
54. Potential Triazole-based Molecules for the Treatment of Neglected Diseases. Mantoani SP; de Andrade P; Chierrito TPC; Figueredo AS; Carvalho I Curr Med Chem; 2019; 26(23):4403-4434. PubMed ID: 28748757 [TBL] [Abstract][Full Text] [Related]
55. Drug discovery and human African trypanosomiasis: a disease less neglected? Ferrins L; Rahmani R; Baell JB Future Med Chem; 2013 Oct; 5(15):1801-41. PubMed ID: 24144414 [TBL] [Abstract][Full Text] [Related]
56. 2-Arylindoles: a privileged molecular scaffold with potent, broad-ranging pharmacological activity. Lal S; Snape TJ Curr Med Chem; 2012; 19(28):4828-37. PubMed ID: 22830349 [TBL] [Abstract][Full Text] [Related]
57. Bioprospecting of Nitrogenous Heterocyclic Scaffolds with Potential Action for Neglected Parasitosis: A Review. Albino SL; da Silva JM; de C Nobre MS; de M E Silva YMS; Santos MB; de Araújo RSA; do C A de Lima M; Schmitt M; de Moura RO Curr Pharm Des; 2020; 26(33):4112-4150. PubMed ID: 32611290 [TBL] [Abstract][Full Text] [Related]
58. Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases. Ravera M; Moreno-Viguri E; Paucar R; Pérez-Silanes S; Gabano E Eur J Med Chem; 2018 Jul; 155():459-482. PubMed ID: 29908440 [TBL] [Abstract][Full Text] [Related]
59. Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits. Blaazer AR; Orrling KM; Shanmugham A; Jansen C; Maes L; Edink E; Sterk GJ; Siderius M; England P; Bailey D; de Esch IJ; Leurs R J Biomol Screen; 2015 Jan; 20(1):131-40. PubMed ID: 25231971 [TBL] [Abstract][Full Text] [Related]
60. Recent Studies on Neglected Drug Design. de Sousa NF; Scotti L; Rodrigues GCS; de Moura ÉP; Costa Barros RPB; Sessions ZL; Muratov EN; Scotti MT Curr Top Med Chem; 2021; 21(21):1943-1974. PubMed ID: 34544342 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]